Endo International Plc (ENL.TO) 63.37 $ENL.TO
Endo Health Solutions Inc. Announces Receipt of Requisite Tenders and Consents in the Exchange Offers and Consent Solicitations Relating to its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7A 1/4% Senior Notes due 2022
PR Newswire Europe - Thu Apr 17, 7:01AM CDT
Endo International plc ("Endo" or the "Company"
announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI", has received requisite tenders and consents in connection with its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019 (the "2019 Existing EHSI Notes", 7.00% Senior Notes due 2020 (the "2020 Existing EHSI Notes" and 7A 1/4% Senior Notes due 2022 issued by EHSI (the "2022 Existing EHSI Notes" and, together with the 2019 Existing EHSI Notes and the 2020 Existing EHSI Notes, the "Existing EHSI Notes", for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes", respectively, to be issued by Endo Finance LLC and Endo Finco Inc. and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries, and the related solicitation of consents to amend the Existing EHSI Notes and the indentures governing the Existing EHSI Notes. Consents were solicited in respect of the indentures governing each series of the Existing EHSI Notes to approve proposed amendments that would, among other things, (i) delete in their entirety substantially all the restrictive covenants in each indenture, (ii) modify the covenants regarding mergers and consolidations, and (iii) eliminate certain events of default. Capitalized terms used but not defined herein shall have the meanings ascribed to them in EHSI's Offer to Exchange dated March 27, 2014 (as amended from time to time, the "Offer to Exchange".
Endo Health Solutions Inc. Announces Receipt of Requisite Tenders and Consents in the Exchange Offers and Consent Solicitations Relating to its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7¼% Senior Notes due 2022
PR Newswire - Thu Apr 17, 7:00AM CDT
Endo International plc (NASDAQ: ENDP) (TSX: ENL) ("Endo" or the "Company" announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI", has received requisite tenders and consents in connection with its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019 (the "2019 Existing EHSI Notes", 7.00% Senior Notes due 2020 (the "2020 Existing EHSI Notes" and 7¼% Senior Notes due 2022 issued by EHSI (the "2022 Existing EHSI Notes" and, together with the 2019 Existing EHSI Notes and the 2020 Existing EHSI Notes, the "Existing EHSI Notes", for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes", respectively, to be issued by Endo Finance LLC and Endo Finco Inc. and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries, and the related solicitation of consents to amend the Existing EHSI Notes and the indentures governing the Existing EHSI Notes. Consents were solicited in respect of the indentures governing each series of the Existing EHSI Notes to approve proposed amendments that would, among other things, (i) delete in their entirety substantially all the restrictive covenants in each indenture, (ii) modify the covenants regarding mergers and consolidations, and (iii) eliminate certain events of default. Capitalized terms used but not defined herein shall have the meanings ascribed to them in EHSI's Offer to Exchange dated March 27, 2014 (as amended from time to time, the "Offer to Exchange".
Endo to Announce First Quarter 2014 Financial Results on May 1, 2014
PR Newswire Europe - Tue Apr 15, 3:01PM CDT
Endo International plc will announce its first quarter 2014 financial results before the open of the U.S. financial markets on May 1, 2014 and members of its senior management team will host a conference call and webcast at 7:30 a.m. ET that day.
Endo Health Solutions Inc. Amends Exchange Offers and Consent Solicitations for its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022
PR Newswire Europe - Mon Apr 14, 7:02AM CDT
Endo International plc ("Endo" or the "Company" announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI", has amended the terms of its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022 issued by EHSI (collectively, the "Existing EHSI Notes", for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes", respectively, to be issued by Endo Finance LLC and Endo Finco Inc. (together, the "Endo Finance Issuers" and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries, and the related solicitation of consents to amend the Existing EHSI Notes and the indentures governing the Existing EHSI Notes. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Offer to Exchange (as defined below).
Endo Health Solutions Inc. Announces Extension of Consent Date and Expiration Date in Exchange Offers and Consent Solicitations for its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7-1/4% Senior Notes due 2022
PR Newswire Europe - Fri Apr 11, 7:02AM CDT
Endo International plc ("Endo" or the "Company" announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI", has further extended the consent date and expiration date in its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7A 1/4% Senior Notes due 2022 issued by EHSI (collectively, the "Existing EHSI Notes", for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes", respectively, to be issued by Endo Finance LLC and Endo Finco Inc. (together, the "Endo Finance Issuers" and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries (collectively, the "Guarantors", and the related solicitation of consents to amend the Existing EHSI Notes and the indentures governing the Existing EHSI Notes. Capitalized terms used but not defined herein shall have the meanings ascribed to them in EHSI's Offer to Exchange dated March 27, 2014.
Ampio Pharmaceuticals' Vyrix Enters into an Agreement with Paladin Labs for Exclusive Rights to Zertane(TM) in Canada and Other Territories to Broaden its International Footprint
PR Newswire - Thu Apr 10, 7:00AM CDT
Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE) today announced that its wholly-owned subsidiary Vyrix Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing late-stage prescription pharmaceuticals to improve men's sexual health, has signed an agreement with Paladin Labs Inc., a leading Canadian specialty pharmaceutical company, to provide exclusive rights to market, sell and distribute Zertane(TM) in Canada, the Republic of South Africa, Sub-Saharan Africa and Latin America.
Louis Van Amstel, Former Dancing with the Stars Professional, Joins "Making Your Move" Campaign to Raise Awareness of Osteoarthritis
PR Newswire Europe - Wed Apr 09, 6:01AM CDT
-- Campaign with Endo Pharmaceuticals and HealthyWomen Encourages Osteoarthritis Joint Pain Sufferers to 'Get Up and Get Active'
Endo International plc Announces Endo Health Solutions Inc. Will Commence Exchange Offers
PR Newswire Europe - Thu Mar 27, 11:53PM CDT
Endo International plc ("Endo" or the "Company" announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI", will commence offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7A 1/4% Senior Notes due 2022 issued by EHSI, which have an aggregate principal amount outstanding of $1.3 billion (collectively, the "Existing EHSI Notes", for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes", respectively, issued by Endo Finance LLC ("Endo Finance" and Endo Finco Inc. ("Endo Finco" and, together with Endo Finance, the "Endo Finance Issuers" and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries (collectively, the "Guarantors". The exchange offers will commence on March 27, 2014 and will expire at 11:59 p.m., New York City time, on April 23, 2014, unless extended or terminated (the "Expiration Date". The exchange of each series of the Existing EHSI Notes for the corresponding series of New Endo Finance Notes will be conducted on a par-for-par basis, subject to downward adjustment for tenders submitted after 11:59 p.m., New York City time, on April 9, 2014 (as it may be extended or terminated, the "Consent Date". The terms and conditions of the exchange offers appear in the offering documents, which will be distributed to the holders of Existing EHSI Notes who complete and return a letter of eligibility confirming that they are "Eligible Holders" for the purposes of the exchange offers and the related consent solicitations. Endo expressly reserves the right to waive these conditions in whole or in part at any or at various times in its sole discretion.
Endo Announces Appointment of Dr. Susan Hall as New Chief Scientific Officer and Global Head of R&D and Quality
PR Newswire Europe - Fri Mar 07, 6:31AM CST
Endo International plc announced today that it had appointed Susan Hall, Ph.D. as executive vice president, chief scientific officer and global head of research & development and quality, effective March 10, 2014. Dr. Hall will be based in Dublin, Ireland at Endo's new global corporate headquarters.
U.S. FDA Approves AVEED(TM) (Testosterone Undecanoate) Injectable Testosterone Replacement Therapy For Men Living With Hypogonadism, Or Low-T
PR Newswire - Thu Mar 06, 6:00AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today that its operating company Endo Pharmaceuticals Inc. received U.S. Food and Drug Administration (FDA) approval of AVEED(TM) (testosterone undecanoate) injection for the treatment of adult men with hypogonadism (commonly known as Low-T) that is associated with a deficiency or absence of the male hormone testosterone. AVEED is a new prescription medicine indicated to produce serum testosterone levels in the normal range by administration of a single 3-mL (750 mg) intramuscular injection given once at initiation of therapy, at 4 weeks, and then every 10 weeks thereafter. It is expected to be available in early March.
Endo International acquires Paladin Labs for USD2.7bn
M2 - Mon Mar 03, 5:21AM CST
Health care company Endo International (Endo Health Solutions) (Nasdaq:ENDP)(TSX:ENL) reported on Friday the completion of its acquisition of Paladin Labs, valued at USD2.7bn, in a stock and cash transaction.
Endo Health Solutions Inc. Announces Receipt of Requisite Tenders and Consents in the Exchange Offers and Consent Solicitations Relating to its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7A 1/4% Senior Notes due 2022
PR Newswire Europe - Thu Apr 17, 7:01AM CDT
Endo International plc ("Endo" or the "Company"
announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI", has received requisite tenders and consents in connection with its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019 (the "2019 Existing EHSI Notes", 7.00% Senior Notes due 2020 (the "2020 Existing EHSI Notes" and 7A 1/4% Senior Notes due 2022 issued by EHSI (the "2022 Existing EHSI Notes" and, together with the 2019 Existing EHSI Notes and the 2020 Existing EHSI Notes, the "Existing EHSI Notes", for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes", respectively, to be issued by Endo Finance LLC and Endo Finco Inc. and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries, and the related solicitation of consents to amend the Existing EHSI Notes and the indentures governing the Existing EHSI Notes. Consents were solicited in respect of the indentures governing each series of the Existing EHSI Notes to approve proposed amendments that would, among other things, (i) delete in their entirety substantially all the restrictive covenants in each indenture, (ii) modify the covenants regarding mergers and consolidations, and (iii) eliminate certain events of default. Capitalized terms used but not defined herein shall have the meanings ascribed to them in EHSI's Offer to Exchange dated March 27, 2014 (as amended from time to time, the "Offer to Exchange". Endo Health Solutions Inc. Announces Receipt of Requisite Tenders and Consents in the Exchange Offers and Consent Solicitations Relating to its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7¼% Senior Notes due 2022
PR Newswire - Thu Apr 17, 7:00AM CDT
Endo International plc (NASDAQ: ENDP) (TSX: ENL) ("Endo" or the "Company"
announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI", has received requisite tenders and consents in connection with its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019 (the "2019 Existing EHSI Notes", 7.00% Senior Notes due 2020 (the "2020 Existing EHSI Notes" and 7¼% Senior Notes due 2022 issued by EHSI (the "2022 Existing EHSI Notes" and, together with the 2019 Existing EHSI Notes and the 2020 Existing EHSI Notes, the "Existing EHSI Notes", for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes", respectively, to be issued by Endo Finance LLC and Endo Finco Inc. and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries, and the related solicitation of consents to amend the Existing EHSI Notes and the indentures governing the Existing EHSI Notes. Consents were solicited in respect of the indentures governing each series of the Existing EHSI Notes to approve proposed amendments that would, among other things, (i) delete in their entirety substantially all the restrictive covenants in each indenture, (ii) modify the covenants regarding mergers and consolidations, and (iii) eliminate certain events of default. Capitalized terms used but not defined herein shall have the meanings ascribed to them in EHSI's Offer to Exchange dated March 27, 2014 (as amended from time to time, the "Offer to Exchange". Endo to Announce First Quarter 2014 Financial Results on May 1, 2014
PR Newswire Europe - Tue Apr 15, 3:01PM CDT
Endo International plc will announce its first quarter 2014 financial results before the open of the U.S. financial markets on May 1, 2014 and members of its senior management team will host a conference call and webcast at 7:30 a.m. ET that day.
Endo Health Solutions Inc. Amends Exchange Offers and Consent Solicitations for its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022
PR Newswire Europe - Mon Apr 14, 7:02AM CDT
Endo International plc ("Endo" or the "Company"
announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI", has amended the terms of its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022 issued by EHSI (collectively, the "Existing EHSI Notes", for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes", respectively, to be issued by Endo Finance LLC and Endo Finco Inc. (together, the "Endo Finance Issuers" and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries, and the related solicitation of consents to amend the Existing EHSI Notes and the indentures governing the Existing EHSI Notes. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Offer to Exchange (as defined below). Endo Health Solutions Inc. Announces Extension of Consent Date and Expiration Date in Exchange Offers and Consent Solicitations for its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7-1/4% Senior Notes due 2022
PR Newswire Europe - Fri Apr 11, 7:02AM CDT
Endo International plc ("Endo" or the "Company"
announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI", has further extended the consent date and expiration date in its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7A 1/4% Senior Notes due 2022 issued by EHSI (collectively, the "Existing EHSI Notes", for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes", respectively, to be issued by Endo Finance LLC and Endo Finco Inc. (together, the "Endo Finance Issuers" and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries (collectively, the "Guarantors", and the related solicitation of consents to amend the Existing EHSI Notes and the indentures governing the Existing EHSI Notes. Capitalized terms used but not defined herein shall have the meanings ascribed to them in EHSI's Offer to Exchange dated March 27, 2014. Ampio Pharmaceuticals' Vyrix Enters into an Agreement with Paladin Labs for Exclusive Rights to Zertane(TM) in Canada and Other Territories to Broaden its International Footprint
PR Newswire - Thu Apr 10, 7:00AM CDT
Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE) today announced that its wholly-owned subsidiary Vyrix Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing late-stage prescription pharmaceuticals to improve men's sexual health, has signed an agreement with Paladin Labs Inc., a leading Canadian specialty pharmaceutical company, to provide exclusive rights to market, sell and distribute Zertane(TM) in Canada, the Republic of South Africa, Sub-Saharan Africa and Latin America.
Louis Van Amstel, Former Dancing with the Stars Professional, Joins "Making Your Move" Campaign to Raise Awareness of Osteoarthritis
PR Newswire Europe - Wed Apr 09, 6:01AM CDT
-- Campaign with Endo Pharmaceuticals and HealthyWomen Encourages Osteoarthritis Joint Pain Sufferers to 'Get Up and Get Active'
Endo International plc Announces Endo Health Solutions Inc. Will Commence Exchange Offers
PR Newswire Europe - Thu Mar 27, 11:53PM CDT
Endo International plc ("Endo" or the "Company"
announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI", will commence offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7A 1/4% Senior Notes due 2022 issued by EHSI, which have an aggregate principal amount outstanding of $1.3 billion (collectively, the "Existing EHSI Notes", for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes", respectively, issued by Endo Finance LLC ("Endo Finance" and Endo Finco Inc. ("Endo Finco" and, together with Endo Finance, the "Endo Finance Issuers" and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries (collectively, the "Guarantors". The exchange offers will commence on March 27, 2014 and will expire at 11:59 p.m., New York City time, on April 23, 2014, unless extended or terminated (the "Expiration Date". The exchange of each series of the Existing EHSI Notes for the corresponding series of New Endo Finance Notes will be conducted on a par-for-par basis, subject to downward adjustment for tenders submitted after 11:59 p.m., New York City time, on April 9, 2014 (as it may be extended or terminated, the "Consent Date". The terms and conditions of the exchange offers appear in the offering documents, which will be distributed to the holders of Existing EHSI Notes who complete and return a letter of eligibility confirming that they are "Eligible Holders" for the purposes of the exchange offers and the related consent solicitations. Endo expressly reserves the right to waive these conditions in whole or in part at any or at various times in its sole discretion. Endo Announces Appointment of Dr. Susan Hall as New Chief Scientific Officer and Global Head of R&D and Quality
PR Newswire Europe - Fri Mar 07, 6:31AM CST
Endo International plc announced today that it had appointed Susan Hall, Ph.D. as executive vice president, chief scientific officer and global head of research & development and quality, effective March 10, 2014. Dr. Hall will be based in Dublin, Ireland at Endo's new global corporate headquarters.
U.S. FDA Approves AVEED(TM) (Testosterone Undecanoate) Injectable Testosterone Replacement Therapy For Men Living With Hypogonadism, Or Low-T
PR Newswire - Thu Mar 06, 6:00AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today that its operating company Endo Pharmaceuticals Inc. received U.S. Food and Drug Administration (FDA) approval of AVEED(TM) (testosterone undecanoate) injection for the treatment of adult men with hypogonadism (commonly known as Low-T) that is associated with a deficiency or absence of the male hormone testosterone. AVEED is a new prescription medicine indicated to produce serum testosterone levels in the normal range by administration of a single 3-mL (750 mg) intramuscular injection given once at initiation of therapy, at 4 weeks, and then every 10 weeks thereafter. It is expected to be available in early March.
Endo International acquires Paladin Labs for USD2.7bn
M2 - Mon Mar 03, 5:21AM CST
Health care company Endo International (Endo Health Solutions) (Nasdaq:ENDP)(TSX:ENL) reported on Friday the completion of its acquisition of Paladin Labs, valued at USD2.7bn, in a stock and cash transaction.
